Neosuxa100 mg/2 ml

Neosuxa is a depolarizing neuromuscular blocking agent used exclusively in hospital and emergency settings under the supervision of clinicians trained in airway management and general anesthesia. It is never used for self-administration or outpatient/home use.

Established (FDA-approved) uses

• As an adjunct to general anesthesia, to produce skeletal muscle relaxation and facilitate endotracheal intubation in adults and pediatric patients.
• To facilitate mechanical ventilation in intubated patients during surgery.

Guideline-supported / emergency use

• Rapid sequence induction and intubation (RSI) in emergency airway management (emergency department, pre-hospital, and critical-care intubation), including in pediatric patients, where its rapid onset and short duration are advantageous when a difficult airway, laryngospasm, or full-stomach (aspiration risk) situation is anticipated.

Uses requiring combination therapy

• Neosuxa is always given together with sedative/induction agents (e.g., propofol, ketamine, etomidate) as part of a rapid sequence induction protocol; it has no sedative, analgesic, or amnestic effect of its own.

Because of its boxed-warning risks (see Precautions and Warnings), Neosuxa is reserved for situations where its rapid onset and short duration of action provide a clear clinical advantage over non-depolarizing agents.

Suxamethonium Chloride is available as a sterile injectable solution for intravenous or intramuscular use, typically supplied in ampoules or vials as suxamethonium chloride (succinylcholine chloride) dihydrate, at strengths such as 50 mg/mL. Some presentations are supplied as a dilute, ready-to-use solution (e.g., in dextrose or saline) intended for continuous infusion. Each pack states the exact strength and diluent on the label; always confirm the labeled strength before use.

Neosuxa (also known as succinylcholine chloride) is the only depolarizing neuromuscular blocking agent in routine clinical use. It produces very rapid onset (about 30-60 seconds) and very short duration (about 4-10 minutes) of complete skeletal muscle paralysis, making it the agent of choice when immediate control of the airway is required. It is administered only by, or under the direct supervision of, personnel trained in general anesthesia or emergency airway management, in a setting equipped for immediate tracheal intubation and ventilatory support.

Neosuxa belongs to the therapeutic class of depolarizing skeletal muscle relaxants (neuromuscular blocking agents), used as an anesthesia adjunct.

Mechanism: Suxamethonium Chloride acts as an agonist at nicotinic acetylcholine receptors on the motor end-plate of skeletal muscle. Its initial depolarization produces transient muscle fasciculations, followed by sustained depolarization that renders the end-plate unresponsive to further stimulation, producing flaccid paralysis (Phase I block). With repeated or prolonged dosing, the blockade characteristics can change to resemble a non-depolarizing block (Phase II block).

Pharmacokinetics: Onset of action after intravenous injection is approximately 30-60 seconds, with maximal blockade in about 1-2 minutes and spontaneous recovery of muscle function within 4-10 minutes, because Suxamethonium Chloride is rapidly hydrolyzed by plasma (pseudo)cholinesterase to succinylmonocholine and then choline and succinic acid. Individuals with genetically reduced or atypical plasma cholinesterase activity may experience markedly prolonged paralysis and apnea (see Use in Special Populations).

Neosuxa is given as a rapid intravenous injection (bolus) for intubation, or as a slow intravenous infusion (diluted to 1-2 mg/mL in 5% dextrose or 0.9% sodium chloride) for procedures requiring sustained relaxation. When intravenous access cannot be obtained, it may be given by intramuscular injection, with a slightly delayed onset (2-3 minutes). It must never be self-administered. Diluted infusion solutions should be freshly prepared, refrigerated if not used immediately, and discarded within 24 hours. The undiluted product should be inspected for particulate matter or discoloration before use and discarded if either is present.

The following clinically significant interactions apply to Neosuxa:

• Cholinesterase inhibitors (e.g., neostigmine, pyridostigmine, echothiophate eye drops, organophosphate pesticides) and drugs that reduce plasma cholinesterase activity (e.g., oral contraceptives, glucocorticoids, cyclophosphamide, monoamine oxidase inhibitors) can markedly prolong the neuromuscular block and apnea.
• Volatile inhalational anesthetics (e.g., halothane, isoflurane, desflurane) increase the risk of triggering malignant hyperthermia and can potentiate neuromuscular blockade (see Precautions and Warnings).
• Digoxin, beta-blockers, and other bradycardia-inducing agents can worsen the bradycardia/arrhythmia risk associated with Neosuxa, particularly with repeat dosing.
• Drugs that raise serum potassium (e.g., potassium-sparing diuretics) can compound the hyperkalemic effect of Neosuxa.
• Magnesium salts, lithium, and quinidine/quinine can potentiate neuromuscular blockade and prolong recovery.
• Prior administration of a non-depolarizing neuromuscular blocker can alter (usually antagonize, sometimes potentiate depending on agent/timing) the effect of Neosuxa; sequencing should be managed by the anesthesia provider.

Reported adverse effects of Neosuxa include:

• Cardiovascular: bradycardia (especially in children and after a second dose), tachycardia, hypertension, hypotension, cardiac arrhythmias, and rarely cardiac arrest.
• Hyperkalemia, which can precipitate life-threatening arrhythmias (see Precautions and Warnings).
• Malignant hyperthermia in susceptible individuals (see Precautions and Warnings).
• Musculoskeletal: muscle fasciculations, postoperative muscle pain/myalgia, jaw rigidity/masseter spasm, and rarely rhabdomyolysis with myoglobinuria and acute kidney injury.
• Respiratory: prolonged apnea or respiratory depression, particularly in patients with reduced plasma cholinesterase activity.
• Other: excessive salivation, increased intraocular and intracranial pressure, increased intragastric pressure, skin rash, and severe anaphylactic/anaphylactoid reactions (including rare fatalities).

Most effects resolve spontaneously as Neosuxa is rapidly metabolized, but they require the immediate availability of resuscitation facilities during administration.

Pregnancy: Published data have not identified a Neosuxa-associated increase in major birth defects, miscarriage, or adverse maternal/fetal outcomes, and it is commonly used as part of general anesthesia for cesarean delivery. At usual clinical doses only small amounts cross the placenta. However, plasma cholinesterase activity is physiologically reduced by roughly 20-30% in pregnancy, which can prolong the drug's effect in the mother. Neosuxa should be used in pregnancy only when clearly needed, with the potential benefit weighed against potential risk, and only by an anesthesia provider aware of the pregnancy.

Lactation: There are no data on the presence of Neosuxa in human milk or its effects on a breastfed infant; because of its very short plasma half-life and use as a single peri-operative dose, clinically significant infant exposure is considered unlikely, but a physician should be consulted regarding breastfeeding after anesthesia.

Neosuxa carries several serious, potentially fatal risks and must be used only by personnel trained in general anesthesia/advanced airway management with resuscitation equipment immediately available.

Malignant hyperthermia

In genetically susceptible individuals, Neosuxa can trigger malignant hyperthermia, a life-threatening hypermetabolic crisis of skeletal muscle presenting with rapidly rising body temperature, muscle rigidity, tachycardia, and metabolic acidosis. Risk is increased when given together with volatile inhalational anesthetics. If suspected, all triggering agents must be stopped immediately, dantrolene sodium administered, and full supportive/cooling measures instituted.

Hyperkalemia

Neosuxa can cause a transient rise in serum potassium in normal patients and a severe, potentially fatal rise in patients with burns, major trauma, neuromuscular disease, extensive denervation, or prolonged immobilization; this risk increases with the time elapsed since the injury/illness (see Contraindications for the specific higher-risk window).

Rhabdomyolysis and undiagnosed myopathy in children

Rare cases of acute rhabdomyolysis with hyperkalemia, followed by ventricular arrhythmias and cardiac arrest, have occurred in apparently healthy children later found to have an undiagnosed skeletal muscle myopathy (e.g., Duchenne muscular dystrophy). Because of this, routine (non-emergency) use of Neosuxa in children is discouraged; it should be reserved for emergency intubation or securing an airway that cannot otherwise be managed (e.g., laryngospasm, difficult airway, full stomach) or for intramuscular use when intravenous access is not available.

Anaphylaxis

Severe, sometimes fatal, anaphylactic/anaphylactoid reactions have been reported with Neosuxa and other neuromuscular blockers. Facilities for treatment of anaphylaxis must always be immediately available.

Medication errors

Unintended administration causes paralysis and respiratory arrest; Neosuxa ampoules/vials should be stored and handled in a way that clearly distinguishes them from other medicines to avoid mix-ups.

Bradycardia

Neosuxa can cause profound bradycardia or asystole, particularly in children and after repeat dosing; pretreatment with an anticholinergic (e.g., atropine) may be used at the anesthesia provider's discretion.

Prolonged neuromuscular block

Individuals with genetically reduced/atypical plasma cholinesterase, or with liver disease, malnutrition, or certain drug therapy, may experience markedly prolonged paralysis and apnea requiring continued ventilatory support until recovery.

Raised intraocular, intracranial, and intragastric pressure

Transient rises in these pressures can occur; caution is required in penetrating eye injury (contraindicated), raised intracranial pressure, and patients at risk of aspiration.

Overdose or excessive sensitivity to Neosuxa presents as prolonged neuromuscular blockade beyond the expected duration, causing muscle weakness, inadequate spontaneous breathing, low tidal volume, or complete apnea. This is a medical emergency: the patient's airway must be secured and ventilation supported (manually or mechanically) until neuromuscular function recovers; there is no specific antidote. Any suspected overdose or unexpectedly prolonged paralysis should prompt immediate escalation to senior anesthesia/critical-care staff and continuous cardiorespiratory monitoring; this is not a situation for home management, and immediate medical/emergency attention is required.

Store Neosuxa in a refrigerator at 2°C to 8°C, protected from light, unless the specific product labeling states otherwise (some presentations permit a limited period at controlled room temperature - check the pack insert). Diluted infusion solutions should be refrigerated if not used immediately and discarded within 24 hours of preparation. Keep out of reach of children, and store separately from other injectable medicines to avoid selection errors.

Pediatric patients: Reserve Neosuxa for emergency intubation/airway securing rather than routine elective anesthesia, because of the risk of hyperkalemic cardiac arrest in children with undiagnosed myopathy (see Precautions and Warnings). Higher mg/kg doses are needed than in adults.

Elderly patients: Data on age-related differences are limited; use cautiously at the lower end of the dosing range, considering reduced cardiac, hepatic, and renal reserve and higher likelihood of comorbidities/co-medications.

Hepatic/renal impairment: Plasma cholinesterase production may be reduced in liver disease, and clearance of metabolites may be reduced in renal impairment, both of which can prolong the drug's action; use with caution and monitor neuromuscular recovery.

Genetically reduced or atypical plasma cholinesterase (pseudocholinesterase deficiency): These individuals may develop markedly prolonged paralysis and apnea after even a single standard dose and require extended ventilatory support.

Pregnancy and lactation: See Pregnancy and Lactation section.

Neosuxa is used strictly as a single dose or short continuous infusion for the duration of a specific procedure (intubation or surgery), typically lasting from a few minutes up to the length of the operative procedure under continuous monitoring. It has no role in ongoing/chronic or take-home treatment, and repeat dosing beyond what is needed for the procedure is avoided because of the risk of prolonged (Phase II) block.

Suxamethonium Chloride belongs to the drug class of depolarizing neuromuscular blocking agents, within the broader category of skeletal muscle relaxants used in anesthesia.

Suxamethonium Chloride mimics acetylcholine at the neuromuscular junction, binding nicotinic receptors on the motor end-plate and causing sustained depolarization. Because it is not rapidly broken down by acetylcholinesterase at the synapse (only by plasma cholinesterase, more slowly, after diffusing away), the end-plate remains depolarized and unresponsive to further nerve impulses, producing flaccid skeletal muscle paralysis until the drug is cleared from the circulation.

C

Use of Neosuxa in pediatric patients (neonates through adolescents) is restricted to emergency intubation or situations where the airway must be secured immediately and no safer alternative is practical (e.g., laryngospasm, anticipated difficult airway, or a full stomach with aspiration risk), or for intramuscular use when intravenous access cannot be obtained. Routine, non-emergency use of Neosuxa in children is not recommended because rare but fatal hyperkalemic cardiac arrest has occurred in children with undiagnosed skeletal muscle myopathy. Children generally require a higher dose per kilogram than adults (2 mg/kg in infants/small children; 1 mg/kg in older children and adolescents for IV use), and bradycardia is more common in this age group, so pretreatment with an anticholinergic agent may be considered.